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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer death in men and women in the United States. It is estimated that in 2012, a total of 143,460 U.S. men and women will be diagnosed with cancer of the colon and rectum (1) . Family history is a strong risk factor for colorectal cancer (2, 3) , which is consistent with the existence of shared etiologic and genetic determinants among relatives. Known genetic mutations account for about 30-50% of the familial risk (4) ; much of the remaining familial aggregation is unexplained. Genome-wide association studies (GWAS) of sporadic CRC have identified at least 20 independent loci statistically significantly associated with risk (5) (6) (7) (8) (9) (10) (11) (12) . However, these variants cumulatively explain only a very small fraction of CRC risk (13) .
Beyond inherited risk, there is a large body of evidence supporting the role of nongenetic factors, including vitamin D status, in the etiology of CRC. The first human evidence to suggest an association between vitamin D and CRC was the ecologic study by Garland and Garland based on data collected in the 1950's and 60's which showed a strong inverse association between colon cancer mortality and solar ultraviolet B (UVB) radiation exposure in the U.S. (14). Since then, most but not all case-control and cohort studies have found an inverse association between intake of vitamin D (both diet and supplements) and CRC risk (15) (16) (17) (18) , with even stronger associations observed using directly measured circulating 25(OH)D (19) (20) (21) (22) , an have not demonstrated reductions in colorectal cancer incidence. However, these trials have generally tested low doses of vitamin D and each included less than seven years of follow-up, which is likely insufficient to shown an effect on cancer incidence, particularly in light of the Vitamin D genetics GECCO: Manuscript long latency of disease. Similarly, large meta-analyses of clinical trials have not shown robust evidence for a protective role of vitamin D in the development of colorectal cancer (26) despite some indication of a preventative role in the development of adenomas (27) .
Circulating 25(OH)D levels are a function of dietary sources and exposure of the skin to sunlight, specifically UVB rays. In addition to environmental determinants, twin and family studies suggest that genetic factors contribute substantially to circulating vitamin D levels, with heritability estimates ranging from 43 to 80% (28) (29) (30) (31) . 
Materials and Methods
Study Population
The analysis included a total of 10,061 cases and 12,768 controls of European ancestry drawn from 13 studies within GECCO and CCFR. Details on the studies are provided in Table 1, and are described in detail in the Supplemental Note and Supplemental Table 1 . In brief, each study defined CRC cases as colorectal adenocarcinoma, confirmed by medical records, pathologic reports, or death certificates. All participants provided informed consent and studies were approved by their respective Institutional Review Boards. None of the studies included in GECCO or CCFR contributed subjects to the any previous GWAS of 25(OH)D with the exception of a subset of the NHS subjects (n=1,342) who participated in the validation stage of one study (33) .
Genotyping, Quality Assurance/Quality Control and Imputation
We used genotype data from GECCO and CCFR. GECCO Set 1, and DALS Set 1) was done using Illumina HumanHap 550K, 610K, or combined Illumina 300K and 240K, and has been described previously (12) . A total of 650 CRC cases and 522 controls from OFCCR are included in GECCO from previous genotyping using Affymetrix platforms (35) . A total of 5,540 CRC cases and 5,425 controls from ASTERISK, Colo2&3, DACHS, DALS Set 2, MEC, PMH, PLCO Set 2, VITAL, and WHI Set 2 were successfully genotyped using Illumina HumanCytoSNP. A total of 2,004 CRC cases and 2,244 controls from HPFS (2 sets), NHS (2 sets), and PHS (2 sets) were successfully genotyped using Illumina HumanOmniExpress. The CCFR included a population-based case-control set of participants from sites in USA, Canada, and Australia successfully genotyped using Illumina Human1M or Human1M-Duo (36).
DNA was extracted from samples of white blood cells or, in the case of a subset of NHS, HPFS, DACHS, MEC, and PLCO samples, and all VITAL samples from buccal cells using conventional methods (37) . All studies included 1 to 6% blinded duplicates to monitor quality of the genotyping. All individual-level genotype data were managed centrally at University of Southern California (CCFR), the Ontario Institute for Cancer Research (OFCCR), the University of Washington (HPFS, NHS, and PHS), or the GECCO and CCFR Coordinating Center (CC) at the Fred Hutchinson Cancer Research Center (all other studies) to ensure consistent quality assurance and quality control (QA/QC) and statistical analysis. Details on the QA/QC can be found in Supplemental Table 2 . In brief, samples were excluded based on call rate, heterozygosity, unexpected duplicates, gender discrepancy, and unexpectedly high identity-by- GECCO studies were imputed to HapMap II release 24, with the exception of OFCCR, which was imputed to HapMap II release 22. CCFR was imputed using IMPUTE (38) , OFCCR was imputed using BEAGLE (39), and all other studies were imputed using MACH (40) 
Dietary and Lifestyle Factors
Dietary information, including calcium, folate, fiber and alcohol intake, was available for Colo2&3, DALS, HPFS, MEC, NHS, PLCO I, PLCO II, VITAL, WHI; calcium, folate and alcohol was available in PHS; and calcium and alcohol in ASTERISK and DACHS. Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) was available for CCFR, Colo2&3, DACHS, HPFS, MEC, NHS and VITAL. All studies collected data on smoking status, red meat consumption, physical activity, body mass index, and hormone replacement therapy in postmenopausal women with the exception of ASTERISK. ASTERISK was restricted to cases with no family history of colorectal cancer. We adopted a flexible approach to retrospective covariate harmonization as previously described (41, 42) .
Laboratory Assessment of 25(OH)D
In previous studies, we measured plasma levels of 25(OH)D in a subset of the cases and controls with genetic data that were nested within the NHS, HPFS, and PHS (total cases n=672 and total controls n=909) using a radioimmunosorbent assay in the laboratory of Dr. Bruce W. HPFS, and 13.8% in PHS. Cases and their controls were analyzed in the same batch, and laboratory personnel were blinded to case, control, and quality-control status (21, 43, 44) .
Statistical Analyses
The statistical analyses of the GECCO and CCFR samples were conducted at a central data analysis center on individual-level data to ensure a consistent analytical approach. For each study, we estimated the association between each SNP and risk for CRC by calculating betas, odds ratios (ORs), standard errors, 95% confidence intervals (CIs), and p-values using logadditive genetic models relating the genotype dose (0, 1 or 2 copies of the allele) to risk of CRC.
For imputed SNPs, we used the dosage (expected number of copies of the minor allele) when testing associations, which has been shown to give unbiased estimates (45) . We also created a genetic risk score (GRS), comprised of four SNPs from four distinct gene regions to ensure no single gene was over represented in the score using an allelic scoring system based on summing the number of risk alleles (previously associated with lower 25(OH)D), yielding a possible range of 0-8 alleles to derive estimates of allelic OR.
Minimally adjusted models included covariates for age, sex (when appropriate), center (when appropriate), smoking status, batch effects (ASTERISK only), and the first three principal components from EIGENSTRAT to account for population substructure. Multivariate models were additionally adjusted for family history of CRC, BMI, NSAID use, alcohol use, dietary calcium, folate and red meat intake, sedentary status, and hormone replacement therapy based on covariate availability. We repeated the minimally adjusted model analyses stratified by anatomical site (colon and rectum). We conducted inverse-variance weighted, fixed-effects meta-analysis to combine beta estimates and standard errors from log-additive models across individual studies. We chose to focus on fixed-effects to improve power and assessed heterogeneity across studies utilizing random effects models (46) . For analyses of the joint effect of plasma 25(OH)D and our GRS comprised of 25(OH)Dassociated SNPs, we included the 672 cases and 909 controls in NHS, HPFS, and PHS among whom we had previously measured pre-diagnostic levels of 25(OH)D and also had genotype data (21, 44) . We calculated ORs and 95% CI for CRC comparing extreme quartiles of 25(OH)D defined according to cohort-specific cutpoints determined by the distribution in controls (44) .
We compared the GRS-associated risk for CRC across categories of high versus low vitamin D levels and quartiles of vitamin D, as well as tested for multiplicative interactions between GRS and a 1ng/mL increase in 25(OH)D and high/low vitamin D using a product term in the model and assessing its significance by the Wald method.
We used PLINK, R (47, 48) and SAS 9.2 (SAS Institute Inc, Cary, NC) to conduct the statistical analyses. We estimated our power to detect an association between a GRS and CRC using the method of Tosteson et al. (49) . These calculations account for the strength of association between the vitamin D SNPs and circulating 25(OH)D.
Results
Our study included 10,061 CRC cases and 12,768 controls. Overall 53% were female, and the mean age at CRC diagnosis was 64.0 years (+/-9.6 SD), 55.0% past/current smokers and with risk allele frequencies ranging from 16 -61%. Table 1 
then fully adjusted, did not demonstrate a statistically significant association with CRC risk (Table 2 ). In analyses stratified by anatomic site each of the four SNP associations remained non-significant (Table 3) Prior studies have examined individual SNPs in CYP24A1 or GC (66, 67) in association with risk of CRC. A prior DALS multicenter population-based case-control study of 1,600 CRC cases found a statistically significant association between one CYP24A1 polymorphism and overall risk of colon cancer, particularly for proximal colon cancer, as well as an association between three CYP24A1 polymorphisms and distal colon cancer (67) . However, the correlation between these CYP24A1 genetic markers investigated by the DALS study and the CYP24A1 marker examined in this full combined analysis study is very low (r 
between our GRS and 25(OH)D of r=0.17, with a 10 ng/ml increase in 25(OH)D associated with OR=0.74 for CRC (22) , our power to detect a 1-allele change in our GRS is 96% (significance level of 0.05). However, if the true magnitude of association with a 10ng/mL increase in 25(OH)D is in fact an OR of 0.85 for CRC, we would have only had 56% power to detect a 1-allele change in our GRS.
We are not certain of the precise pathway or biological mediators by which 25(OH)D influences CRC risk. Our GRS assumes that each included SNP would be associated with increased CRC risk according to their observed association with lower 25(OH)D. If this assumption is invalid, combining the alleles into this GRS would reduce our power to detect associations with CRC. If we remove the GC SNP and repeat our power calculation, our observed correlation between our GRS and 25(OH)D becomes r=0.11, resulting in 68% power to detect a 1 allele change in our proxy score.
We acknowledge some limitations. First, our study includes only populations of European descent, which limits the generalizability of our findings. However, the circulating 25(OH)D SNPs that we examined were identified in GWAS of populations of European descent, and so the underlying genetic associations should hold in our study population. Moreover, limiting our analysis to European descent populations minimizes the potential for confounding by population structure. Second, if these SNPs are correlated with another locus that influences the risk of CRC, this could confound our results (73) . Third, despite our large sample size, we had limited power to detect associations between individual SNPs and risk of CRC. 
